ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - lopinavir; ritonavir - תמיסה (פומי) - ritonavir 20 mg/ml; lopinavir 80 mg/ml - ritonavir - ritonavir - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - lopinavir; ritonavir - טבליות מצופות פילם - lopinavir 100 mg; ritonavir 25 mg - ritonavir - ritonavir - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infections.

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - lopinavir; ritonavir - טבליות מצופות פילם - ritonavir 50 mg; lopinavir 200 mg - lopinavir - lopinavir - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - lopinavir; ritonavir - טבליות מצופות פילם - ritonavir 50 mg; lopinavir 200 mg - lopinavir - lopinavir - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - lopinavir; ritonavir - תמיסה (פומי) - ritonavir 20 mg/ml; lopinavir 80 mg/ml - ritonavir

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - lopinavir; ritonavir - תמיסה (פומי) - ritonavir 20 mg/ml; lopinavir 80 mg/ml - ritonavir

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd - niacin 500 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd - niacin 750 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd - niacin 1000 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

ישראל - עברית - Ministry of Health

bristol - myers squibb, israel - atazanavir as sulfate - קפסולות - atazanavir as sulfate 200 mg - atazanavir - atazanavir - reyataz is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.